**Name of journal: World Journal of Clinical Infectious Diseases**

**ESPS Manuscript NO: 5443**

**Columns: REVIEW**

**Is there an unrecognised role for *Campylobacter* infections in (chronic) inflammatory diseases?**

Louwen R *et al*. *Campylobacter* infection and inflammation

Rogier Louwen, John P Hays

**Rogier Louwen, John P Hays,** Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Centre Rotterdam, 3015GD Rotterdam, The Netherlands

**Author contributions:** Louwen R and Hays JP both wrote the paper.

**Correspondence to: Dr. Rogier Louwen,** Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Centre Rotterdam, ’s-Gravendijkwal 230, 3015GD Rotterdam, The Netherlands. r.louwen@erasmusmc.nl

**Telephone**: +31-10-7037297 **Fax**: +31-10-7043875

**Received:** September 7, 2013  **Revised:** October 30, 2013

**Accepted:** November 15, 2013

**Published online:**

**Abstract**

*Campylobacter* species are one of the major causes of global bacterial-related diarrheal disease worldwide. The disease is most frequently associated with the ingestion of contaminated meat, raw milk, pets, contaminated water, and the organism may be frequently cultured from the faeces of chicken and other domesticated farm animals. Of the 17 established *Campylobacter* species, the most important pathogens for humans are *Campylobacter jejuni* (*C. jejuni*), *Campylobacter* *coli* (*C.* *coli*) and *Campylobacter* *fetus* (*C.* *fetus*),which are all associated with diarrheal disease. Further, *C. jejuni* and *C.* *coli* are also associated with the neuroparalytic diseases Guillain-Barré syndrome and Miller Fischer syndrome, respectively, whereas *C.* *fetus* is linked with psoriatic arthritis. The discovery of both “molecular mimicry” and translocation-related virulence in the pathogenesis of *C*. *jejuni*-induced disease, indicates, that *Campylobacter*-related gastrointestinal infections may not only generate localized, acute intestinal infection in the human host, but may also be involved in the establishment of chronic inflammatory diseases. Indeed, pathogenicity studies on several *Campylobacter* species now suggest that molecular mimicry and translocation-related virulence is not only related to *C*. *jejuni*, but may play a role in human disease caused by other *Campylobacter* spp. In this review, the authors provide a review based on the current literature describing the potential links between *Campylobacter* spp. and (chronic) inflammatory diseases, and provide their opinions on the likely role of *Campylobacter* in such diseases.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** *Campylobacter* spp; Infection; Autoimmune diseases; Chronic diseases

**Core tip:** *Campylobacter* species are able to induce both gastrointestinal and systemic infections in humans and have been linked not only to acute disease, but also to a wide range of (chronic) inflammatory diseases. In this respect, the organism is particularly associated with inflammatory peripheral nerve disease Guillain-Barré syndrome and reactive arthritis. However, the true role of *Campylobacter* in other human inflammatory diseases remains to be determined. This review indicates that the actual role of *Campylobacter* in human inflammatory diseases may be largely underestimated and suggests that further research is necessary in order to accurately determine the importance of *Campylobacter* infection in these diseases.

Louwen R, Hays JP. Is there an unrecognised role for *Campylobacter* infections in (chronic) inflammatory diseases?

**Available from:** URL: http://www.wjgnet.com/2220-3176/

**DOI:** http://dx.doi.org/10.5495/

**INTRODUCTION**

*Campylobacter* species are Gram negative zoonotic human pathogens that are one of the major causes of global bacterial-related diarrheal disease worldwide, a disease most frequently associated with the ingestion of contaminated animal products such as chicken meat, raw milk, contaminated water, and contaminated farm animals. Currently, of the 17 established *Campylobacter* species the most important associated with human disease is *Campylobacter jejuni* (*C. jejuni*), a leading cause of diarrheal disease worldwide with 400-500 million laboratory confirmed cases each year[1]. Further, this species can be sub-divided into two separate groups based on the presence or absence of sialic acid components attached to carbohydrate residues present on the bacterial outer surface[2]. The transfer of these sialic acid components to the carbohydrate outer surface of *C*. *jejuni* is mediated by the enzymes sialyltransferase Cst-II or Cst-III[3], with the presence of sialic acid conferring a highly pathogenic phenotype to the bacterium that has the potential to cause severe colitis[4], as well as paralytic disease. One such paralytic disease is Guillain-Barré syndrome (GBS), a post-infectious life threatening complication often associated with *C. jejuni* infection[5]. In fact, evidence suggests that GBS is facilitated by bacteria-human cross-reactive antibodies, generated *via* a process called “molecular mimicry”. Essentially, some sialylated carbohydrate lipooligosaccharide (LOS) structures on the *C*. *jejuni* outer membrane possess epitopes that appear similar to certain ganglioside epitopes present on human peripheral nerves. This similarity may result in the production of auto-antibodies that target not only the bacterium, but also human nerves, inducing complement-mediated nerve destruction[5]. Further research has also shown that *C*. *jejuni* strains possessing sialylated LOS structures are significantly more invasive than non-sialylated strains, and are also better able to translocate across the intestinal epithelium[6-8]. In this respect, the authors have previously suggested that infection with *C*. *jejuni* and other *Campylobacter* spp. may actually be linked with a significant number of undetected bacteremias[9], and that the detection of *Campylobacter* species in current blood culture systems might be underrepresented, not least because these systems are not optimized for the special growth requirements of this bacterial generus[10].

Interestingly, Houliston *et al*[11] established that *Campylobacter* spp. are able to synthesize a much broader range of human mimicking glycolipid/glycoprotein structures in their lipopolysaccharides (LPS) and LOS than previously thought, *i*.*e*., *Campylobacter* species are equipped with a set of LPS/LOS genes that allow adaptation to their host, possibly allowing the organism to “hide” from recognition by the host immune system. In this hypothesis, LPS or LOS epitopes that mimic host antigens are expressed on the surface of *Campylobacter* bacteria in order to provide protection against the host immune response (*Campylobacter* antigens being recognized as self-antigens and therefore being less likely to be recognized by the host). However, this type of *Campylobacter* LPS and LOS molecular mimicry could potentially be a trigger for the development of as yet unrecognised inflammatory disease states in susceptible hosts. For example, there already exists many publications describing the role of *C. jejuni* in the aetiology of inflammatory diseases such as GBS and Miller Fischer syndrome (MFS), and the reader is referred to[5] for a recent review on this subject.

Worryingly, there are indications that healthy people may actually be (chronic) carriers of *Campylobacter* bacteria, again suggesting that this bacterium is able to adapt itself to the human host and escape immune recognition[12,13]. To confirm these observations well designed surveillance programs are required in order to identify whether apparently healthy humans can be carriers of *Campylobacter* bacteria[14]. Although the carrier state of *Campylobacter* is not completely clear for humans, it has already been established that various animal species can act as carriers of *Campylobacter* spp. without displaying symptoms[15-19], and animal carriers have been linked to the induction of Campybacteriosis in humans[20-22]. Acute infections with *Campylobacter* species via food products, water or animals may also lead to chronic infections in humans[23,24], specifically when patients are suffering from an immunodeficiency[25-28].

In this review, the authors describe and comment on the current literature regarding the potential role of *Campylobacter* spp. in human (chronic) inflammatory diseases. The authors concentrate first on those immunologically-related diseases where a strong association between *Campylobacter* infection and disease has been shown, and then highlight those diseases where an association with *Campylobacter* infection is weaker, but where further research may be warranted. The authors conclude that there is indeed a potential role for *Campylobacter* spp. in the induction of many different types of (chronic) inflammatory diseases, and that this is most likely related to the link between *Campylobacter* infection, inflammation and molecular mimicry.

**GUILLAIN-BARRÉ AND MILLER FISHER SYNDROME**

The GBS and MF syndrome are (sub)acute inflammatory polyradiculoneuropathies affecting the peripheral nerves of affected patients[5]. GBS and MF patients experience degeneration and demyelination of specific neuronal axons after an episode of gastrointestinal or respiratory infection, with demyelination being triggered by an autoimmune-like response[5]. In GBS patients the muscles in the body become paralysed, whereas in MF patients, only the facial muscles are affected[5].

GBS is also called the Landry-Guillain-Barré-Strohl syndrome and is named after the four scientists that originally discovered and reported on this disease[29]. In 1859 Landry de Thézillat was the first to describe an ascending paralyzing disease in great detail[30], although earlier publications mimicking the disorder of Landry were reported by Auguste François Chomel (1788-1858) in 1828[31] and James Wardrop (1782-1869) in 1834[32]. In 1916 Georges Charles Guillain, Jean-Alexandre Barré, and André Strohl reported on an examination of two soldiers that were suffering from muscular weakness, paresthesias, and muscular pain[33]. In 1927, Draganesco *et al*[34] defined the nomenclature “Guillain-Barré syndrome” to describe this paralyzing disease. In 1982, Rhodes and Tattersfield reported for the first time that the GBS syndrome was associated with *Campylobacter* infection[35], which was later confirmed by Constant *et al*[36] and Kaldor *et* *al*[37]. In all of these studies, it was recognized that diarrhoea often preceded the appearance of Guillain-Barré syndrome, with later bacterial culture and serum diagnostic tests revealing that *C*. *jejuni* was often the causative agent of the intestinal infection that preceded the onset of the GBS syndrome[38-45].

In 1990, it was suggested for the first time that *C*. *jejuni* might stimulate the production of antibodies against the myelin sheet of the peripheral nerves of GBS patients[45]. In this same year Yuki *et* *al*[46]*,* demonstrated that 2 GBS patients possessed high serum IgG titres against GM1 ganglioside following *C*. *jejuni* enteritis. A significant finding as these results greatly accelerated the research on *C*. *jejuni*-induced GBS. Subsequently, multiple research groups confirmed the work by Yuki *et al*[46], linking anti-ganglioside antibodies with *C*. *jejuni*-induced GBS[47-50]. Eventually, other research groups established that certain *C*. *jejuni* serotypes (Penner O:4, O:19 and O:41) were more frequently isolated from GBS patients than from enteritis patients, and that anti-GQ1 antibodies were linked to the onset of Miller Fisher syndrome[51-59]. The results of these findings lead to the hypothesis that there exists a form of “molecular mimicry” between *C*. *jejuni* cell envelope structures and ganglioside structures present on the peripheral nerves of affected patients, suggesting that an immunopathogenic mechanism might be causing damage to the nerves in GBS and MFS disease[60,61]. Indeed, Willison *et* *al*[62]*,* not only showed that monoclonal antibodies raised against the LOS isolated from GBS-inducing *C*. *jejuni* strains reacted with ganglioside structures on the peripheral nerves, but that they possess the potential to block muscle-nerve interactions. The subsequent finding that *C. jejuni* possesses genes that enable the sialylation of its outer membrane LOS further increased the suspicion that molecular mimicry might form the basis for *C*. *jejuni*-induced GBS[63-65]. Though mainly associated with *C*. *jejuni*, research has indicated that molecular mimicry may play roles in human infections associated with several other *Campylobacter* species, particularly with *C*. *coli*[38,41,66,67].

Based on these findings, there is a potential for as yet undescribed *Campylobacter*-human autoimmune interactions at the level of molecular mimicry. Further, these interactions could provide a basis for a range of, as yet undefined, chronic and acute inflammatory *Campylobacter*-associated diseases in humans.

**INFLAMMATORY BOWEL DISEASE**

Inflammatory bowel disease (IBD)is a term used for a group of chronic inflammatory disorders of the gut that includes two major diseases. These are Crohn's disease and ulcerative colitis (diseases associated with alteration of the ileum, colon and rectum leading to cramps, fever and bloody diarrhoea). Currently, the association between *C. jejuni* infection and chronic inflammatory bowel diseases such as Crohn's disease is controversial[25,68]. During a four-year study in 1982 in Belgium, 45 patients were found to exhibit signs of an acute infective colitis. Twenty percent of these patients were found to be positive for *C*. *jejuni,* the bacterium found to be associated with focal colitis, necessitating a differential diagnosis from Crohn's colitis[69]. During the same period, 12 patients were also admitted with an acute attack of inflammatory bowel disease due to an intercurrent infection with bacterial pathogens including *C*. *jejuni*[69]. These data indicate that, in the presence of an acute attack of colitis, an infective etiologic agent should always be sought, and that an attack of chronic idiopathic inflammatory bowel disease may be caused by an intercurrent infection. Van Spreeuwel *et al*[70] compared 22 patients with *C.* *jejuni*-induced colitis against 10 healthy controls, 10 ulcerative colitis patients and 10 Crohn’s disease patients, and concluded from immunological analyses that *C*. *jejuni* colitis can be distinguished from ulcerative colitis and Crohn’s disease patients by IgG containing plasma cells. Also, around the same time, Simson *et al*[71] found that *C*. *jejuni* was associated with acute relapse and abscess formation in Crohn's disease. In a Bulgarian study, Boyanova *et al*[24] analyzed the frequency of *Campylobacter* species isolation from patients with acute enterocolitis, inflammatory bowel disease, and other chronic intestinal diseases. The authors screened 682 Bulgarian patients and established that *Campylobacter* species were detected in patients with acute enterocolitis (7.8%), chronic enterocolitis (6.2%), Crohn's disease (6.2%), ulcerative colitis (3.7%), and irritable bowel syndrome (8.3%)[24]. Further, hippurate-positive *C*. *jejuni* isolates accounted for 62.2% of *Campylobacter* strains. The authors concluded that *Campylobacter* could be one of the causes of chronic intestinal diseases in Bulgaria[24]. Interestingly, Braun *et al*[72] (1994), showed that the expression of a novel autoantibody defined by the *VH3-15* gene could be detected in both IBD and *C*. *jejuni* enterocolitis patients. These authors screened 101 individuals with ulcerative colitis, Crohn's disease or other acute or chronic colitis symptoms. Compared with normal subjects, BK2+ anti-erythrocyte Abs were elevated in most sera from patients with Crohn's disease and ulcerative colitis (including post-colectomy)[72]. However, BK2+ anti-erythrocyte antibodies were also elevated in 10 of 38 non-inflammatory bowel disease patients, all of whom had *C*. *jejuni* enterocolitis[72]. The findings by Braun *et al*[72] tended to suggest that a common immunopathogenetic factor, manifested by VH3-15 B cell activation, may be shared between ulcerative colitis, Crohn's disease, and *C*. *jejuni* enterocolitis. An indirect effect of *C*. *jejuni* in the aetiology of inflammatory bowel disease was suggested by several different studies of Kalischuk *et al*[73], who established that transcytosis of *C*. *jejuni* across gut epithelia allowedother commensal gut flora to also cross the intestinal epithelial barrier[68,73,74]. Apparently, the translocation of commensal flora may result in an inflammatory immune response against the commensal gut flora (luminal antigen translocation hypothesis), a process that is commonly observed in patients suffering from inflammatory bowel disease[75,76]. With respect to population studies, Gradel *et al*[77] (2009) compared 13148 people from 2 Danish counties who had been exposed to *Salmonella* and *Campylobacter* gastroenteritis, with 26216 unexposed individuals. After an average follow-up of 7.5 years, the hazard ratio of first-time inflammatory bowel disease diagnosis was 2.9 (exposed to unexposed), and was raised for both Crohn's disease and ulcerative colitis[77]. In those exposed to *Campylobacter* and *Salmonella* only 1.2% of the studied subjects developed IBD. Thus, while the study identified bacterial exposure as a statistically significant factor in IBD the role of *Campylobacter* seems to be only of relative importance. Following the Danish population, but in a different study (1992-2008), Jess *et al*[78] showed that infection with *Campylobacter* species, confirmed by *Campylobacter* isolation from stool samples, significantly increased the risk of developing IBD. However, contradicting this observation, was the finding that culture negative stool samples were also significantly associated with an increased risk for the development of IBD[78]. The final conclusion of the authors was that the increased risk of IBD after infections with intestinal pathogens might be a result of a detection bias, due to increased testing for such pathogens in this patient group[78]. Subsequently, Riddle *et al*[79] further discussed this conclusion stating that due to study limitations and diagnostic bias there could in fact be several different explanations for finding an association between culture positivity or culture negativity in IBD patients.

A more direct link between a *Campylobacter* species (not *jejuni*), Crohn’s disease and inflammatory bowel disease was observed more recently. In 2009-2011, Zhang *et al*[80] were able to link the presence of *Campylobacter* *concisus* (*C*. *concisus*) to pediatric Crohn’s disease using the techniques of polymerase chain reaction (PCR) bacterial detection and the presence of specific IgG antibody, an observation that has also been associated with adults presenting with inflammatory bowel disease[80-82]. Further, in 2011, Kovach *et al*[83] identified actual *C*. *concisus* proteins that were immunoreactive within patients with Crohn's disease.

However, not all studies have been successful in linking *C. jejuni* (or any other *Campylobacter* species) with inflammatory bowel diseases. In 1984, Blaser *et al*[84] studied 72 Crohn’s disease patients using culture, serology and immunohistochemistry, and concluded that *C*. *jejuni* was not likely to be an etiological agent of Crohn’s disease or chronic ulcerative colitis. In a Scandinavian study using 95 patients with *Campylobacteriosis* it was observedthat 77%-86% patients harbored a raised antibody titre against an antigen mixture comprising seven *C. jejuni*/*coli* strains including a PEN 0:6, 7 isolate, which represented the most common serotype in Scandinavia[85]. In this same study, the authors also analyzed the sera of 56 inflammatory bowel disease patients and found that none reacted with this *C*. *jejuni*/*coli* antigen mixture and concluded that *Campylobacteriosis* was not associated with these chronic diseases[85]. In 1992, a prospective study began by analyzing 64 IBD patients 15 of whom were diagnosed with ulcerative colitis. Stool samples were screened for enteric pathogens, but only a low number of these samples were confirmed to be culture positive. The conclusion of this study was that enteric microorganisms including *C*. *jejuni* only play a minor or indeed a negligible role in the exacerbation of inflammatory bowel disease[86]. Therefore, the link between *C*. *jejuni* and IBD seems to be weak, but based on current literature, *C*. *concisus* might by *Campylobacter* species harboring more potential to be a causative agent of IBD.

**IRRITABLE BOWEL SYNDROME**

Irritable bowel syndrome (IBS) differs from IBD in the fact that IBS is a collection of gut-related disease signs and symptoms with no known aetiological cause. Though they have several symptoms in common, treatments for IBS and IBD vary greatly. Only a minority of IBS reported disease is associated with a post-infection process (PI-IBS)[87], though one of the commonest causes of PI-IBS appears to be *C. jejuni* infection[88]. The main mechanism for inducing *C. jejuni*-related IBS appearing to be the production of cytolethal distending toxin (CDT) by *C. jejuni*[89]. However, experiments in a rat model have indicated that histopathological changes in the gut during *C. jejuni* infection may be caused by both CDT-producing and non-producing isolates[90]. Therefore the role of *C*. *jejuni* CDT in IBS remains a point of discussion. One other mechanism involved in the aetiology of IBS is the promotion of inflammation of the gut tissue via the generation of a “low grade” immune response (involving autoendocrine cells, CD3, CD4 and CD8 lymphocytes) and gut permeability[91].

Recently, it has been suggested that blockage of the PI3K-γ signalling pathway in *Campylobacter* infection may be a means of reducing severe inflammation facilitated by the innate immune system[92]. Indeed, treatment of *C. jejuni* infection with the antibiotic rifamixin in a rat model of IBS infection stopped the development of long-term altered stool function and form (a phenomenon linked to the overgrowth of the small intestine with *C. jejuni* bacteria, and a characteristic IBS-associated phenotype)[93].

**REACTIVE ARTHRITIS (REITER'S SYNDROME)**

Reactive arthritis is an inflammation of the joints which develops whilst suffering/recovering from a recent infection. Though other symptoms also usually develop in addition to arthritis, joint inflammation is the main characteristic of this disease. Any site of infection may be associated with reactive arthritis, including the intestine (the site of infection for *C. jejuni*)[94], with symptoms commonly lasting 3-12 mo, though in some cases, the arthritis may persist long-term[94]. Reiter's syndrome a variant of reactive arthritis is established when the following symptoms occur simultaneously; urethritis, arthritis and conjunctivitis[94].

In 1979, a case report was published that linked a *C*. *jejuni* infection with the induction of reactive arthritis for the first time[95]. In this case report, reactive arthritis developed two weeks after the subject experienced watery diarrhoea containing blood, and was experiencing anorexia, and severe weight loss[95]. The causative agent of the infection was found to be *C*. *jejuni*[95]. In a later study, it was established that reactive arthritis was more likely to occur in *C*. *jejuni* enteritis patients that were positive for histocompatability antigen HLA-B27[96], and around the same time period different groups more or less confirmed this finding[97-99]. Importantly, HLA-B27-negative arthritis-related *C*. *jejuni* enteritis cases are nevertheless sporadically reported[97,100-105]. Interestingly, patients presenting with ankylosing spondylitis (a chronic inflammatory disease) overwhelmingly possess HLA-B27 and molecular mimicry with the gut bacterium *Klebsiella pneumoniae* is thought to play a key role in disease development[106,107]. However, research has indicated that there are no signs of *C*. *jejuni*/*coli*-related antibodies in patients with active ankylosing spondylitis[108]. More recently, Mortensen *et al*[4] was able to link a potential virulence factor, namely class A sialylated lipooligosaccharide structures, to a more severe gastro-enteritis phenotype and reactive arthritis, suggesting that sialylated LOS structures, structures that mimic human gangliosides, are also a risk factor in the development of reactive arthritis. Interestingly, the possession/expression of reactive arthritis-related sialylated LOS structures does not appear to be related to any particular *C. jejuni* genotype[109]. For further information, the reader is referred to a systematic review by Pope *et al*[110], which summarizes the link between *Campylobacter* spp.and reactive arthritis.

Up to this point, there has been strong evidence for an association betwe*en Campylobacter* infection and a range of (chronic) inflammatory diseases, GBS, MF, IDB and IBS. However, in the following section, the authors discuss diseases where the link between *Campylobacter* infection and (chronic) inflammatory disease is much weaker. In this respect, the authors would like to see more research in this area, in order to finally confirm or deny any unrecognised association between *Campylobacter* infection and the following diseases.

**SYSTEMIC LUPUS ERYTHAMATOSUS**

Systemic lupus erythematosus, often abbreviated to SLE or lupus, is a systemic autoimmune disease that can affect any part of the body[111]. As with other autoimmune diseases, the immune system attacks its own cells and tissues, resulting in inflammation and tissue damage[111]. Lupus most often affects the heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous system[111]. The course of the disease is unpredictable, with periods of illness (flares) alternating with remissions. The disease occurs nine times more often in women than in men, mainly in women in the child-bearing years of 15 to 35, and is also more common in those of non-European descent[111]. Currently, over a 100 articles linking SLE with the GBS have been published, one of the main causative agents of GBS being *C. jejuni*[5]. As early as 1984, Blaser *et al*[112] described a persistent *C*. *jejuni* infection in a patient with lupus and a deficiency in serum IgA and IgM. The authors showed that the serum of this patient was not able to kill the *C*. *jejuni* bacterium. In 1998, Gatterbauer *et al*[113] used an ELISA assay to determine the antibody types [IgM, IgG, IgA, and IgG subclass anti-GM1, anti-GQ1b, and anti-asialo-GM1 (anti-GA1)] that were present in patients presenting with neurological or other complicated neurological diseases. Increased anti-GM1 and/or anti-GA1 was found to be more frequent in lupus patients with central nervous system involvement than without[113]. Additionally, in 1999, a case report was published that found antibodies against ganglioside GM1 (indistinguishable from GBS) in the serum of a patient with SLE and a “drop foot”, though no antibodies against *C*. *jejuni* were observed[114]. It has also been reported that an SLE like disease may be triggered in a BALB/c mouse animal model, after immunization of mice with formaldehyde-treated *C*. *jejuni* and Freud’s complete adjuvant[115,116]. However, although *Campylobacter* species may be isolated from lupus patients, it is currently debatable whether *C. jejuni* is the causative agent of lupus disease *per se*, or is simply able to maintain itself in lupus patients due to the immunosuppressive treatment they receive. Particularly interesting are the two articles in which the authors show that they were able to induce an SLE like illness in BALB/c mice using formaldehyde fixed *C*. *jejuni*[115,116].

**CELIAC DISEASE**

Celiac disease is an autoimmune disease in which individuals possess antibodies against gluten protein, a protein found in wheat, barley and rye. Sufferers from celiac disease should avoid eating gluten-containing foodstuffs and therefore are subject to dietary restrictions. At least one report has indicated a role for *C. jejuni* in the aetiology of celiac’s disease[117]. Additionally, a case report was published in 2010 of a girl suffering from celiac disease that was associated with recurrent Guillain-Barré syndrome (*C. jejuni* being one of the main microorganisms proven to be associated with Guillain-Barré syndrome)[118]. Alaedini *et al*[119] showed increased levels of ganglioside antibodies in celiac disease patients, and suggested that a pre-disposition of celiac patients to bacteria possessing cross-reactive lipopolysaccharides (LPS) such as *C. jejuni* (and *Haemophilus influenzae*), may predispose to the development of anti-ganglioside antibodies (similar to the aetiology of Guillain-Barré syndrome). A similar hypothesis involving tissue atrophy and degeneration of mucosa was also proposed by Sabayan *et al*[120] in 2007.

**CARDIOMYOPATHY/MYOCARDITIS**

Cardiomyopathy is a measurable deterioration of the function of the heart muscle, usually leading to heart failure. Common symptoms include breathlessness and peripheral oedema (for example, swelling of the legs). People with cardiomyopathy are often at risk of dangerous forms of irregular heart beat and sudden cardiac death. The most common form of cardiomyopathy is dilated cardiomyopathy. Myocarditis is an inflammation of the myocardium (heart muscle) and is synonymous with the term inflammatory cardiomyopathy. Interestingly, *C*. *jejuni* has been linked to cardiac disease in several case reports[121-136]. Also, more severe cases of *C. jejuni* infection may result in heart failure of the patient[123,128,131]. In 2007, Becker *et al*[137] investigated whether the incidence of perimyocarditis is increased following *C*. *jejuni* infection. Their conclusion after screening 6204 patients for perimyocarditis, and after the patients had experienced a *C*. *jejuni* infection, was that the incidence rate of myocarditis was 16.1 (95%CI: 2.3-114.4) per 100000 person-year in the *Campylobacter* population compared to 1.6 (95%CI: 0.2-11.4) per 100000 person-year in the control cohort[137]. Although this observation was not found to be statistically significant, the authors did conclude that, based on the rarity of this condition and case reports in the literature linking *Campylobacter* cases with perimyocarditis, it could not be ruled out that a potential association between *Campylobacter* and perimyocarditis might exist[137]. Additional research, indicates that there seems to be a tendency for males to be overrepresented in cardiomyopathy patient groups following *C. jejuni* gastroenteritis symptoms[121-126,138-140], which warrants further investigation. Alzand *et al*[125], suggested that the mechanism by which *Campylobacter* causes myo(peri)carditis could be attributed to direct bacterial invasion of cardiac tissue, bacterial toxins, circulating immune complexes, or cytotoxic T-cells. However, at the moment, the mechanisms leading to cardiac disease after *C. jejuni* infection remain unknown, but support the idea that *C*. *jejuni* is able to cause systemic infections[9,10].

At this point in the review, the authors present evidence for an association between infection with *Campylobacter* spp. and (chronic) inflammatory diseases, which is based mainly on case reports in the scientific literature.

**ACUTE TRANSVERSE MYELITIS**

Acute transverse myelitis is a neurological disorder that affects the spinal cord through inflammation, generating for example complications such as axonal demyelination. The disease is associated with an infection or vaccination[141]. In two relatively recent case reports, from 2007 and 2012, acute transverse myelitis was associated with *C*. *jejuni*-induced gastroenteritis[141,142]. Patients were found to harbor cross-reactive antibodies against the sialylated LOS structures of *C*. *jejuni*, specifically high titres of anti-GM1 were observed.

**GLOMERULONEPHRITIS**

Glomerulonephritis is a renal disease that is characterized by inflammation of the glomeruli, or small blood vessels in the kidney[143,144]. It may present with isolated hematuria and/or proteinuria (blood or protein in the urine); or as a nephrotic syndrome, a nephritic syndrome, acute renal failure, or chronic renal failure[144]. Diagnosing the pattern of glomerulonephritis is important because the outcome and treatment differs in different types of glomerular disease[144]. The primary causes of glomerular disease are intrinsic to the kidney[144], but secondary causes of disease may be associated with; certain infections (bacterial, viral or parasitic pathogens), drugs, systemic disorders (SLE, vasculitis), or diabetes[143]. Several case reports have shown a potential link between *C*. *jejuni* infection and glomerular disease[145-150]. In some reports a *C*. *jejuni* antigen was identified in the glomeruli suggesting a causal role for this bacterium in the disease process[145,148].

**VASCULITIS**

Vasculitis is a group of autoimmune diseases in which blood vessels are attacked by the immune system and where inflammation is present[151]. *C*. *fetus* subsp. *intestinalis* was one the first *Campylobacter* species linked to vasculitis and is seen most often in older, debilitated, or chronically ill men[152]. In case reports, *C*. *jejuni* has been linked to patients experiencing various forms of vasculitis[114,146,153-158], though whether an actual causal relationship exists between disease and infection is as yet is unknown.

**PSORIATIC ARTHRITIS**

Psoriatic arthritis is a form of inflammatory arthritis that will develop in up to 30 percent of people who have the chronic skin condition psoriasis[159]. Psoriatic arthritis is said to be a seronegative spondyloarthropathy and therefore occurs more commonly in patients with tissue type HLA-B27[159]. A strong link between anti-*Campylobacter* *fetus* antibodies in psoriatic arthritis patients (rheumatoid arthritis, non-arthritic-psoriasis and psoriatic arthritis patients) was observed in the study of Lapadula *et al*[160]. Currently, no further studies on this subject have been reported, and it should be noted that the patient group used in the Lapadula study was small.

**CANCER**

*C*. *jejuni* is phylogenetically closely related to *Helicobacter* *pylori*, a bacterium established to be a causative agent of gastric cancer[161]. Further, the cytolethal distending toxin of *C. jejuni* may possess DNAse activity and could induce the breakage of double stranded DNA[162], one of the possible steps on the development of cancer. Currently, there is some evidence indicating that *C*. *jejuni* may possibly be linked to the development of mucosa-associated lymphoid tissue (MALT) lymphoma[163-165]. MALT is a cancer type that originates from B cells in the marginal zone of the MALT, and is also called extranodal marginal zone B cell lymphoma. However, a large cohort study of Scandinavian patients who had tested positive for *C*. *jejuni*, and were followed over time (≥ 10 years) showed no increased risk of developing malignancies following an infection by *C*. *jejuni*[166]. Interestingly, the authors did find a decrease in respiratory cancers following an infection by *C. jejuni*.

**CONCLUSION**

*Campylobacter* species are able to induce both gastrointestinal and systemic infections in humans and have been linked not only to acute disease, but also to a wide range of (chronic) inflammatory diseases. In this respect, the organism is particularly associated with the development of neurological diseases such as GBS, MFS, and with reactive arthritis, diseases that are facilitated by the development of cross-reactive antibodies to *Campylobacter* sialylated LOS carbohydrate structures. However, the true role of *Campylobacter*-induced molecular mimicry in other human inflammatory diseases remains to be determined, though this review indicates that the actual role of *Campylobacter* infections in human disease may be largely underestimated. Therefore, further research is required in order to accurately determine the importance of *Campylobacter* infection in a wide range of (chronic) inflammatory diseases of humans.

**REFERENCES**

1. **Ruiz-Palacios GM**. The health burden of Campylobacter infection and the impact of antimicrobial resistance: playing chicken. *Clin Infect Dis* 2007; **44**: 701-703 [PMID: 17278063 DOI: 10.1086/509936]

2. **Penner JL**, Aspinall GO. Diversity of lipopolysaccharide structures in Campylobacter jejuni. *J Infect Dis* 1997; **176** Suppl 2: S135-S138 [PMID: 9396697 DOI: 10.1086/513778]

3. **Godschalk PC**, Kuijf ML, Li J, St Michael F, Ang CW, Jacobs BC, Karwaski MF, Brochu D, Moterassed A, Endtz HP, van Belkum A, Gilbert M. Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barré and Miller Fisher syndromes. *Infect Immun* 2007; **75**: 1245-1254 [PMID: 17261613 DOI: 10.1128/IAI.00872-06]

4. **Mortensen NP**, Kuijf ML, Ang CW, Schiellerup P, Krogfelt KA, Jacobs BC, van Belkum A, Endtz HP, Bergman MP. Sialylation of Campylobacter jejuni lipooligosaccharides is associated with severe gastro-enteritis and reactive arthritis. *Microbes Infect* 2009; **11**: 988-994 [PMID: 19631279 DOI: 10.1016/j.micinf.2009.07.004]

5. **van Doorn PA**, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. *Lancet Neurol* 2008; **7**: 939-950 [PMID: 18848313 DOI: 10.1016/S1474-4422(08)70215-1]

6. **Habib I**, Louwen R, Uyttendaele M, Houf K, Vandenberg O, Nieuwenhuis EE, Miller WG, van Belkum A, De Zutter L. Correlation between genotypic diversity, lipooligosaccharide gene locus class variation, and Caco-2 cell invasion potential of Campylobacter jejuni isolates from chicken meat and humans: contribution to virulotyping. *Appl Environ Microbiol* 2009; **75**: 4277-4288 [PMID: 19411422 DOI: 10.1128/AEM.02269-08]

7. **Louwen R**, Heikema A, van Belkum A, Ott A, Gilbert M, Ang W, Endtz HP, Bergman, MP, Nieuwenhuis EE. The sialylated lipooligosaccharide outer core in Campylobacter jejuni is an important determinant for epithelial cell invasion. *Infect Immun* 2008; 76: 4431-4438 [PMID: 18644887 DOI: 10.1128/IAI.00321-08]

8. **Louwen R**, Nieuwenhuis EE, van Marrewijk L, Horst-Kreft D, de Ruiter L, Heikema AP, van Wamel WJ, Wagenaar JA, Endtz HP, Samsom J, van Baarlen P, Akhmanova A, van Belkum A. Campylobacter jejuni Translocation across Intestinal Epithelial Cells Is Facilitated by Ganglioside-Like Lipooligosaccharide Structures. *Infect Immun* 2012; **80**: 3307-3318 [PMID: 22778098 DOI: 10.1128/IAI.06270-11]

9. **Louwen R**, van Baarlen P, van Vliet AHM, van Belkum A., Hays JP, Endtz HP Campylobacter BACTEREMIA: A RARE AND UNDER-REPORTED EVENT? *Euro J Microbiol Immunol* 2012; **2**: 76-87

10. **Wang WL**, Blaser MJ. Detection of pathogenic Campylobacter species in blood culture systems. *J Clin Microbiol* 1986; **23**: 709-714 [PMID: 3700626]

11. **Houliston RS**, Vinogradov E, Dzieciatkowska M, Li J, St Michael F, Karwaski MF, Brochu D, Jarrell HC, Parker CT, Yuki N, Mandrell RE, Gilbert M. Lipooligosaccharide of Campylobacter jejuni: similarity with multiple types of mammalian glycans beyond gangliosides. *J Biol Chem* 2011; **286**: 12361-12370 [PMID: 21257763 DOI: 10.1074/jbc.M110.181750]

12. **Coker AO**, Isokpehi RD, Thomas BN, Amisu KO, Obi CL. Human Campylobacteriosis in developing countries. *Emerg Infect Dis* 2002; **8**: 237-244 [PMID: 11927019 DOI: 10.3201/eid0803.010233]

13. **Lastovica A**. Campylobacter spp.: The tip of the iceberg. *Clin Microbiol* 2006; **28**: 49-55 [DOI: 10.1016/j.clinmicnews.2006.03.004]

14. **Wagenaar JA**, Endtz HP, Fernandez H, Vagsholm I, French N, Sow AG, Havelaar AH, Hofacre CL, Kalupahana R, Keddy KH, Vandenberg O, Lake R, Nachamkin I, Zhao S, Qaddoura KMT, Tauxe R, Kostenzer K, Takkinen J, Riddle MS, van Pelt W, Speksnijder DC, van Gompel L, Molbak K, Cahill S, Abela-Ridder B, Cartagena P. The global view of Campylobacteriosis. *Report of an expert consultation* 2012: 1-57

15. **Burnens AP**, Angeloz-Wick B, Nicolet J. Comparison of *Campylobacter* carriage rates in diarrheic and healthy pet animals. *Zentralbl Veterinarmed B* 1992; **39**: 175-180 [PMID: 1642073 DOI: 10.1111/j.1439-0450]

16. **Prescott JF**, Bruin-Mosch CW. Carriage of Campylobacter jejuni in healthy and diarrheic animals. *Am J Vet Res* 1981; **42**: 164-165 [PMID: 7224312]

17. **Baker J**, Barton MD, Lanser J. Campylobacter species in cats and dogs in South Australia. *Aust Vet J* 1999; **77**: 662-666 [PMID: 10590795 DOI: 10.1111/j.1751-0813]

18. **Horrocks SM**, Anderson RC, Nisbet DJ, Ricke SC. Incidence and ecology of Campylobacter jejuni and coli in animals. *Anaerobe* 2009; **15**: 18-25 [PMID: 18849005 DOI: 10.1016/j.anaerobe.2008.09.001]

19. **Newell DG**, Elvers KT, Dopfer D, Hansson I, Jones P, James S, Gittins, J, Stern NJ, Davies R, Connerton I, Pearson D, Salvat G, Allen VM. Biosecurity-based interventions and strategies to reduce Campylobacter spp. on poultry farms. *Appl Environ Microbiol* 2011; **77**: 8605-8614 [PMID: 21984249 DOI: 10.1128/AEM.01090-10]

20. **Sahin O**, Fitzgerald C, Stroika S, Zhao S, Sippy RJ, Kwan P, Plummer PJ, Han J, Yaeger MJ, Zhang Q. Molecular evidence for zoonotic transmission of an emergent, highly pathogenic Campylobacter jejuniclone in the United States. *J Clin Microbiol* 2012; **50**: 680-687 [PMID: 22189122 DOI: 10.1128/JCM.06167-11]

21. **French NP**, Midwinter A, Holland B, Collins-Emerson J, Pattison R, Colles F, Carter P. Molecular epidemiology of Campylobacter jejuni isolates from wild-bird fecal material in children's playgrounds. *Appl Environ Microbiol* 2009; **75**: 779-783 [PMID: 19047378 DOI: 10.1128/AEM.01979-08]

22. **Hald B**, Madsen M. Healthy puppies and kittens as carriers of Campylobacter spp., with special reference to Campylobacter upsaliensis. *J Clin Microbiol* 1997; **35**: 3351-3352 [PMID: 9399557]

23. **Lecuit M**, Abachin E, Martin A, Poyart C, Pochart P, Suarez F, Bengoufa D, Feuillard J, Lavergne A, Gordon JI, Berche P, Guillevin L, Lortholary O. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. *N Engl J Med* 2004; **350**: 239-248 [PMID: 14724303 DOI: 10.1016/j.dld.2012.03.020]

24. **Boyanova L**, Gergova G, Spassova Z, Koumanova R, Yaneva P, Mitov I, Derejian S, Krastev, Z. Campylobacter infection in 682 bulgarian patients with acute enterocolitis, inflammatory bowel disease, and other chronic intestinal diseases. *Diagn Microbiol Infect Dis* 2004; **49**: 71-74 [PMID: 15135505]

25. **Riddle MS**, Gutierrez RL, Verdu EF, Porter CK. The chronic gastrointestinal consequences associated with Campylobacter. *Curr Gastroenterol Rep* 2012; **14**: 395-405 [PMID: 22864805 DOI: 10.1007/s11894-012-0278-0]

26. **van den Bruele T**, Mourad-Baars PE, Claas EC, van der Plas RN, Kuijper EJ, Bredius RG. Campylobacter jejuni bacteremia and Helicobacter pylori in a patient with X-linked agammaglobulinemia. *Eur J Clin Microbiol Infect Dis* 2010; **29**: 1315-1319 [PMID: 20556465 DOI: 10.1007/s10096-010-0999-7]

27. **Krause R**, Ramschak-Schwarzer S, Gorkiewicz G, Schnedl WJ, Feierl G, Wenisch C, Reisinger EC. Recurrent septicemia due to Campylobacter fetus and Campylobacter lari in an immunocompetent patient. *Infection* 2002; **30**: 171-174 [PMID: 12120946 DOI: 10.1007/s15010-002-2115-0]

28. **Peterson MC**. Clinical aspects of Campylobacter jejuni infections in adults. *West J Med* 1994; **161**: 148-152 [PMID: 7941533]

29. **Afifi AK**. The landry-guillain-barre strohl syndrome 1859 to 1992 a historical perspective. *J Family Community Med* 1994; **1**: 30-34 [PMID: 23008532]

30. **Landry**. Notesur la paralysie ascendante gigue. *Gazette Hebdomadaire* 1859; **6**: 472-474

31. **Chomel AF**. An epidemic of acute polyneuritis formed the basis for Chomel's original description. *J Hebdomadaire de Médecine* 1828; **1**: 333

32. **Wardrop J**. Note sur la paralysie ascendante aiguë. *Gazette hebdomadaire de médecine et de chirurgie* 1834; **6**: 472-474

33. **Guillain G**, Barré JA, Strohl A. [Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes. 1916]. *Ann Med Interne (Paris)* 1999; **150**: 24-32 [PMID: 10400560]

34. **Draganesco H**, Claudian J. Sur un cas de radiculu-névrite curable (syndrome de Guillain-Barré) apparue au cours d’une ostéomyélite du bras. *Revue Neurologique* 1927; **2**: 517-521

35. **Rhodes KM**, Tattersfield AE. Guillain-Barré syndrome associated with Campylobacter infection. *Br Med J (Clin Res Ed)* 1982; **285**: 173-174 [PMID: 6807396 DOI: 10.1136/bmj.285.6336.173]

36. **Constant OC**, Bentley CC, Denman AM, Lehane JR, Larson HE. The Guillain-Barré syndrome following Campylobacter enteritis with recovery after plasmapheresis. *J Infect* 1983; **6**: 89-91 [PMID: 6886449 DOI: 10.1016/S0163-4453(83)95881-4]

37. **Speed B**, Kaldor J, Cavanagh P. Guillain-Barré syndrome associated with Campylobacter jejuni enteritis. *J Infect* 1984; **8**: 85-86 [PMID: 6699419]

38. **Speed BR**, Kaldor J, Watson J, Newton-John H, Tee W, Noonan D, Dwyer BW. Campylobacter jejuni/Campylobacter coli-associated Guillain-Barr syndrome. Immunoblot confirmation of the serological response. *Med J Aust* 1987; **147**: 13-16 [PMID: 3626926]

39. **Sovilla JY**, Regli F, Francioli PB. Guillain-Barré syndrome following Campylobacter jejuni enteritis. Report of three cases and review of the literature. *Arch Intern Med* 1988; **148**: 739-741 [PMID: 3277576]

40. **Clavelou P**, Beytout J, Gourdiat A, Garandeau A, Deffond D, Tournilhac M. [Neurologic involvement in campylobacter infections. 5 cases]. *Rev Neurol (Paris)* 1989; **145**: 208-214 [PMID: 2664975]

41. **Gruenewald R**, Ropper AH, Lior H, Chan J, Lee R, Molinaro VS. Serologic evidence of Campylobacter jejuni/coli enteritis in patients with Guillain-Barré syndrome. *Arch Neurol* 1991; **48**: 1080-1082 [PMID: 1929902 DOI: 10.1001/archneur.1991.00530220102027]

42. **Yamada S**, Bandoh M, Nagura H, Yamanouchi H, Inamatsu T. [Guillain-Barré syndrome preceded by diarrhea with the infection of Campylobacter jejuni]. *Rinsho Shinkeigaku* 1991; **31**: 882-884 [PMID: 1764866]

43. **Boucquey D**, Sindic CJ, Lamy M, Delmee M, Tomasi JP, Laterre EC. Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome. *J Neurol Sci* 1991; **104**: 56-63 [PMID: 1655983 DOI: 10.1016/0022-510X(91)90216-T]

44. **Mishu B**, Ilyas AA, Koski CL, Vriesendorp F, Cook SD, Mithen FA, Blaser MJ. Serologic evidence of previous Campylobacter jejuniinfection in patients with the Guillain-Barré syndrome. *Ann Intern Med* 1993; **118**: 947-953 [PMID: 8489109 DOI: 10.7326/0003-4819-118-12-199306150-00006]

45. **Fujimoto S**, Amako K. Guillain-Barré syndrome and Campylobacter jejuni infection. *Lancet* 1990; **335**: 1350 [PMID: 1971411 DOI: 10.1016/0140-6736(90)91234-2]

46. **Yuki N**, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. *Neurology* 1990; **40**: 1900-1902 [ PMID: 2247243]

47. **Nobile-Orazio E**, Carpo M, Meucci N, Grassi MP, Capitani E, Sciacco M, Mangoni A, Scarlato G. Guillain-Barré syndrome associated with high titers of anti-GM1 antibodies. *J Neurol Sci* 1992; **109**: 200-206 [PMID: 1634903 DOI: 10.1016/0022-510X(92)90169-L]

48. **Gregson NA**, Koblar S, Hughes RA. Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features. *Q J Med* 1993; **86**: 111-117 [PMID: 8464986]

49. **Vriesendorp FJ**, Mishu B, Blaser MJ, Koski CL. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. *Ann Neurol* 1993; **34**: 130-135 [PMID: 8338337 DOI: 10.1002/ana.410340206]

50. **Seiser A**, Potzl G, Safoschnik G, Pichler S, Bernheimer H, Schwerer B. GM 1 antibodies in Guillain-Barré syndrome: isotypes, course and clinical outcome. *Wien Klin Wochenschr* 1994; **106**: 159-163 [PMID: 8197746]

51. **Kuroki S**, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, Nakanishi H. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. *Ann Neurol* 1993; **33**: 243-247 [PMID: 8498807 DOI: 10.1002/ana.410330304]

52. **Aspinall GO**, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. *Biochemistry* 1994; **33**: 241-249 [PMID: 8286348 DOI: 10.1021/bi00167a032]

53. **Aspinall GO**, McDonald AG, Pang H. Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of O antigen chains from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. *Biochemistry* 1994; **33**: 250-255 [PMID: 7506928 DOI: 10.1021/bi00167a033]

54. **Lastovica AJ**, Goddard EA, Argent AC. Guillain-Barré syndrome in South Africa associated with Campylobacter jejuni O:41 strains. *J Infect Dis* 1997; **176**: S139-S143 [PMID: 9396698 DOI: 10.1086/513796]

55. **Nagayama S**, Kurohara K, Matsui M, Kuroda Y, Kusunoki S. [A case of axonal form of Guillain-Barré syndrome associated with anti-GM1b IgG antibody following Penner 4 Campylobacter jejuni infection]. *Rinsho Shinkeigaku* 1997; **37**: 506-508 [PMID: 9366179]

56. **Goddard EA**, Lastovica AJ, Argent AC. *Campylobacter* 0:41 isolation in Guillain-Barré syndrome. *Arch Dis Child* 1997; **76**: 526-528 [PMID: 9245852 DOI: 10.1136/adc.76.6.526]

57. **Prendergast MM**, Lastovica AJ, Moran AP. Lipopolysaccharides from Campylobacter jejuni O:41 strains associated with Guillain-Barré syndrome exhibit mimicry of GM1 ganglioside. *Infect Immun* 1998; **66**: 3649-3655 [PMID: 9673245]

58. **Goffette S**, Jeanjean A, Pierret F, Peeters A, Sindic CJ. Clinical relevance of the determination of anti-GQ1b antibodies in Miller Fisher and Guillain-Barré syndromes. *Acta Neurol Belg* 1998; **98**: 322-326 [PMID: 9922819]

59. **Schwerer B**, Neisser A, Bernheimer H. Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection. *Infect Immun* 1999; **67**: 2414-2420 [PMID: 10225903]

60. **Yuki N**. Pathogenesis of Guillain-Barré and Miller Fisher syndromes subsequent to Campylobacter jejuni enteritis. *Jpn J Infect Dis* 1999; **52**: 99-105 [PMID: 10507987]

61. **Yuki N**. Molecular mimicry between gangliosides and lipopolysaccharides of *Campylobacter* *jejuni* isolated from patients with Guillain-Barré syndrome and Miller Fisher syndrome. *J Infect Dis* 1997; **176**: S150-S153 [PMID: 9396700 DOI: 10.1086/513800]

62. **Goodyear CS**, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, Cochrane L, Bullens RW, Molenaar PC, Conner J, Willison HJ. Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. *J Clin Invest* 1999; **104**: 697-708 [PMID: 10491405 DOI: 10.1172/JCI6837E1]

63. **van Belkum A**, van den Braak N, Godschalk P, Ang W, Jacobs B, Gilbert M, Wakarchuk W, Verbrugh H, Endtz H. A Campylobacter jejuni gene associated with immune-mediated neuropathy. *Nat Med* 2001; **7**: 752-753 [PMID: 11433317 DOI: 10.1038/89831]

64. **Godschalk PC**, Heikema AP, Gilbert M, Komagamine T, Ang CW, Glerum J, Brochu D, Li J, Yuki N, Jacobs BC, van Belkum A, Endtz HP. The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barré syndrome. *J Clin Invest* 2004; **114**: 1659-1665 [PMID: 15578098 DOI: 10.1172/JCI200415707]

65. **Godschalk PC**, van Belkum A, van den Braak N, van Netten D, Ang CW, Jacobs BC, Gilbert M, Endtz HP. PCR-restriction fragment length polymorphism analysis of Campylobacter jejuni genes involved in lipooligosaccharide biosynthesis identifies putative molecular markers for Guillain-Barré syndrome. *J Clin Microbiol* 2007; **45**: 2316-2320 [PMID: 17507514 DOI: 10.1128/JCM.00203-07]

66. **Bersudsky M**, Rosenberg P, Rudensky B, Wirguin I. Lipopolysaccharides of a Campylobacter coli isolate from a patient with Guillain-Barré syndrome display ganglioside mimicry. *Neuromuscul Disord* 2000; **10**: 182-186 [PMID: 10734265 DOI: 10.1016/S0960-8966(99)00106-6]

67. **van Belkum A**, Jacobs B, van Beek E, Louwen R, van Rijs W, Debruyne L, Gilbert M, Li J, Jansz A, Megraud F, Endtz H. Can Campylobacter coli induce Guillain-Barré syndrome? *Eur J Clin Microbiol Infect Dis* 2009; **28**: 557-560 [PMID: 19002726 DOI: 10.1007/s10096-008-0661-9]

68. **Kalischuk LD**, Buret AG. A role for Campylobacter jejuni-induced enteritis in inflammatory bowel disease? *Am J Physiol Gastrointest Liver Physiol* 2010; **298**: G1-G9 [PMID: 19875702 DOI: 10.1152/ajpgi.00193.2009]

69. **Rutgeerts P**, Geboes K, Ponette E, Coremans G, Vantrappen G. Acute infective colitis caused by endemic pathogens in western Europe: endoscopic features. *Endoscopy* 1982; **14**: 212-219 [PMID: 7140655 DOI: 10.1055/s-2007-1021624]

70. **van Spreeuwel JP**, Duursma GC, Meijer CJ, Bax R, Rosekrans PC, Lindeman J. *Campylobacter* colitis: histological immunohistochemical and ultrastructural findings. *Gut* 1985; **26**: 945-951 [PMID: 4029720]

71. **Simson JN**, Ayling R, Stoker TA. Campylobacter jejuni associated with acute relapse and abscess formation in Crohn's disease. *J R Coll Surg Edinb* 1985; **30**: 397 [PMID: 3831348]

72. **Berberian LS**, Valles-Ayoub Y, Gordon LK, Targan SR, Braun J. Expression of a novel autoantibody defined by the VH3-15 gene in inflammatory bowel disease and Campylobacter jejuni enterocolitis. *J Immunol* 1994; **153**: 3756-3763 [PMID: 7930592]

73. **Kalischuk LD**, Leggett F, Inglis GD. Campylobacter jejuni induces transcytosis of commensal bacteria across the intestinal epithelium through M-like cells. *Gut Pathog* 2010; **2**: 14 [PMID: 21040540 DOI: 10.1186/1757-4749-2-14]

74. **Kalischuk LD**, Inglis GD, Buret AG. Campylobacter jejuni induces transcellular translocation of commensal bacteria via lipid rafts. *Gut Pathog* 2009; **1**: 2 [PMID: 19338680 DOI: 10.1186/1757-4749-1-2]

75. **García Rodríguez LA**, Ruigómez A, Panés J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. *Gastroenterology* 2006; **130**: 1588-1594 [PMID: 16697722]

76. **Newman A**, Lambert JR. Campylobacter jejuni causing flare-up in inflammatory bowel disease. *Lancet* 1980; **2**: 919 [PMID: 6107569 DOI: 10.1016/S0140-6736(80)92078-4]

77. **Gradel KO**, Nielsen HL, Schonheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after *Salmonella* or *Campylobacter* gastroenteritis. *Gastroenterology* 2009; **137**: 495-501 [PMID: 19361507 DOI: 10.1053/j.gastro.2009.04.001]

78. **Jess T**, Simonsen J, Nielsen NM, Jorgensen KT, Bager P, Ethelberg S, Frisch M. Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. *Gut* 2011; **60**: 318-324 [PMID: 21193449 DOI: 10.1136/gut.2010.223396]

79. **Riddle MS**, Porter CK. Detection bias and the association between inflammatory bowel disease and Salmonella and Campylobacter infection. *Gut* 2012; **61**: 635 [PMID: 21730102 DOI: 10.1136/gutjnl-2011-300617]

80. **Zhang L**, Man SM, Day AS, Leach ST, Lemberg DA, Dutt S, Stormon M, Otley A, O'Loughlin EV, Magoffin A, Ng PH, Mitchell H. Detection and isolation of *Campylobacter* species other than C. jejuni from children with Crohn's disease. *J Clin Microbiol* 2009; **47**: 453-455 [PMID: 19052183 DOI: 10.1128/JCM.01949-08]

81. **Kaakoush NO**, Mitchell HM. Campylobacter concisus-A New Player in Intestinal Disease. *Front Cell Infect Microbiol* 2012; **2**: 4 [PMID: 22919596 DOI: 10.3389/fcimb.2012.00004]

82. **Man SM**, Zhang L, Day AS, Leach ST, Lemberg DA, Mitchell H. Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn's disease. *Inflamm Bowel Dis* 2010; **16**: 1008-1016 [PMID: 19885905 DOI: 10.1002/ibd.21157]

83. **Kovach Z**, Kaakoush NO, Lamb S, Zhang L, Raftery MJ, Mitchell H. Immunoreactive proteins of Campylobacter concisus, an emergent intestinal pathogen. *FEMS Immunol Med Microbiol* 2011; **63**: 387-396 [PMID: 22092566 DOI: 10.1111/j.1574-695X.2011.00864.x]

84. **Blaser MJ**, Hoverson D, Ely IG, Duncan DJ, Wang WL, Brown WR. Studies of Campylobacter jejuni in patients with inflammatory bowel disease. *Gastroenterology* 1984; **86**: 33-38 [PMID: 6689672]

85. Melby K, Kildebo S. Antibodies against Campylobacter jejuni/coli in patients suffering from campylobacteriosis or inflammatory bowel disease. *NIPH Ann* 1988; **11**: 47-52

86. **Weber P**, Koch M, Heizmann WR, Scheurlen M, Jenss H, Hartmann F. Microbic superinfection in relapse of inflammatory bowel disease. *J Clin Gastroenterol* 1992; **14**: 302-308 [PMID: 1607606]

87. **Longstreth GF**, Hawkey CJ, Mayer EA, Jones RH, Naesdal J, Wilson IK, Peacock RA, Wiklund IK. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. *Aliment Pharmacol Ther* 2001; **15**: 959-964 [PMID: 11421870 DOI: 10.1046/j.1365-2036.2001.01010.x]

88. **Longstreth GF**, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. *Gastroenterology* 2006; **130**: 1480-1491 [PMID: 16678561 DOI: 10.1053/j.gastro.2005.11.061]

89. **Dunlop SP**, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. *Gastroenterology* 2003; **125**: 1651-1659 [PMID: 14724817 DOI: 10.1053/j.gastro.2003.09.028]

90. **Morales W**, Pimentel M, Hwang L, Kunkel D, Pokkunuri V, Basseri B, Low K, Wang H, Conklin JL, Chang C. Acute and chronic histological changes of the small bowel secondary to C. jejuni infection in a rat model for post-infectious IBS. *Dig Dis Sci* 2011; **56**: 2575-2584 [PMID: 21409374 DOI: 10.1007/s10620-011-1662-6]

91. **Spiller RC**, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. *Gut* 2000; **47**: 804-811 [PMID: 11076879 DOI: 10.1136/gut.47.6.804]

92. **Sun X,** Liu B, Sartor RB, Jobin C. Phosphatidylinositol 3-kinase-gamma signaling promotes Campylobacter jejuni-induced colitis through neutrophil recruitment in mice. *J Immunol* 2013; **190**: 357-365 [PMID: 23180818 DOI: 10.4049/jimmunol.1201825]

93. **Pimentel M**, Morales W, Jee SR, Low K, Hwang L, Pokkunuri V, Mirocha J, Conklin J, Chang C. Antibiotic prophylaxis prevents the development of a post-infectious phenotype in a new rat model of post-infectious IBS. *Dig Dis Sci* 2011; **56**: 1962-1966 [PMID: 21222158 DOI: 10.1007/s10620-010-1548-z]

94. **Hamdulay SS**, Glynne SJ, Keat A. When is arthritis reactive? *Postgrad Med J* 2006; **82**: 446-453 [PMID: 16822921 DOI: 10.1136/pgmj.2005.044057]

95. **Berden JH**, Muytjens HL, van de Putte LB. Reactive arthritis associated with Campylobacter jejuni enteritis. *Br Med J* 1979; **1**: 380-381 [PMID: 761021 DOI: 10.1136/bmj.1.6160.380-a]

96. **Kosunen TU**, Kauranen O, Martio J, Pitkanen T, Ponka A, Hortling L, Aittoniemi S, Mutru O, Penttila O, Koskimies S. Reactive arthritis after Campylobacter jejuni enteritis in patients with HLA-B27. *Lancet* 1980; **1**: 1312-1313 [PMID: 6104126 DOI: 10.1016/S0140-6736(80)]

97. **Bremell T**, Bjelle A, Svedhem A. Rheumatic symptoms following an outbreak of Campylobacter enteritis: a five year follow up. *Ann Rheum Dis* 1991; **50**: 934-938 [PMID: 1768164 DOI: 10.1136/ard.50.12.934]

98. **Rynes RI**, Volastro PS, Bartholomew LE. Exacerbation of B27 positive spondyloarthropathy by enteric infections. *J Rheumatol* 1984; **11**: 96-97 [PMID: 6607996]

99. **van de Putte LB**, Berden JH, Boerbooms MT, Muller WH, Rasker JJ, Reynvaan-Groendijk A, van der Linden SM. Reactive arthritis after Campylobacter jejuni enteritis. *J Rheumatol* 1980; **7**: 531-535 [PMID: 7420335]

100. **Engberg JH**, Strid MA, Molbak K, Krogfelt KA. [Antibody response following Campylobacter infections determined by ELISA]. *Ugeskr Laeger* 2003; **165**: 2485-2486 [PMID: 12872469]

101. **Fendler C**, Laitko S, Sorensen H, Gripenberg-Lerche C, Groh A, Uksila J, Granfors K, Braun J, Sieper J. Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. *Ann Rheum Dis* 2001; **60**: 337-343 [PMID: 11247862 DOI: 10.1136/ard.60.4.337]

102. **Pönkä A**, Martio J, Kosunen TU. Reiter's syndrome in association with enteritis due to Campylobacter fetus ssp. jejuni. *Ann Rheum Dis* 1981; **40**: 414-415 [PMID: 7259333 DOI: 10.1136/ard.40.4.414]

103. **Saari KM**, Kauranen O. Ocular inflammation in Reiter's syndrome associated with Campylobacter jejuni enteritis. *Am J Ophthalmol* 1980; **90**: 572-573 [PMID: 7424757]

104. **Leung FY**, Littlejohn GO, Bombardier C. Reiter's syndrome after Campylobacter jejuni enteritis. *Arthritis Rheum* 1980; **23**: 948-950 [PMID: 7406942 DOI: 10.1002/art.1780230813]

105. **Johnsen K**, Ostensen M, Melbye AC, Melby K. HLA-B27-negative arthritis related to Campylobacter jejuni enteritis in three children and two adults. *Acta Med Scand* 1983; **214**: 165-168 [PMID: 6605028 DOI: 10.1111/j.0954-6820.1983.tb08589.x]

106. **Ebringer A**, Rashid T. B27 disease is a new autoimmune disease that affects millions of people. *Ann N Y Acad Sci* 2007; **1110**: 112-120 [PMID: 17911426 DOI: 10.1196/annals.1423.013]

107. **Fielder M**, Pirt SJ, Tarpey I, Wilson C, Cunningham P, Ettelaie C, Binder A, Bansal S, Ebringer A. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. *FEBS Lett* 1995; **369**: 243-248 [PMID: 7649265 DOI: 10.1016/0014-5793(95)00760-7]

108. **Andreasen JJ**, Ringsdal VS, Helin P. No signs of Campylobacter jejuni/coli-related antibodies in patients with active ankylosing spondylitis. *APMIS* 1991; **99**: 735-738 [PMID: 1677583 DOI: 10.1111/j.1699-0463.1991.tb01252.x]

109. **Nielsen LN**, Sheppard SK, McCarthy ND, Maiden MC, Ingmer H, Krogfelt KA. MLST clustering of Campylobacter jejuni isolates from patients with gastroenteritis, reactive arthritis and Guillain-Barré syndrome. *J Appl Microbiol* 2010; **108**: 591-599 [PMID: 19702866 DOI: 10.1111/j.1365-2672.2009.04444.x]

110. **Pope JE**, Krizova A, Garg AX, Thiessen-Philbrook H, Ouimet JM. Campylobacter reactive arthritis: a systematic review. *Semin Arthritis Rheum* 2007; **37**: 48-55 [PMID: 17360026 DOI: 10.1016/j.semarthrit.2006.12.006]

111. **Lipsky PE**. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. *Nat Immunol* 2001; **2**: 764-766 [PMID: 11526379 DOI: 10.1038/ni0901-764]

112. **Johnson RJ**, Nolan C, Wang SP, Shelton WR, Blaser MJ. Persistent Campylobacter jejuni infection in an immunocompromised patient. *Ann Intern Med* 1984; **100**: 832-834 [PMID: 6721298 DOI: 10.7326/0003-4819-100-6-832]

113. **Gatterbauer B**, Neisser A, Bernheimer H, Schwerer B. Antiglycosphingolipid immune responses in neurology. The Vienna experience with isotypes, subclasses, and disease. *Ann N Y Acad Sci* 1998; **845**: 353-362 [PMID: 9668368 DOI: 10.1111/j.1749-6632.1998.tb09687.x]

114. **Matsuki Y**, Hidaka T, Matsumoto M, Fukushima K, Suzuki K. Systemic lupus erythematosus demonstrating serum anti-GM1 antibody, with sudden onset of drop foot as the initial presentation. *Intern Med* 1999; **38**: 729-732 [PMID: 10480305]

115. **Jiang L**, Wang Z, Zhu HW, Di HY, Li H, Zhang YY, Chen DF. Beneficial effect of Eucommia polysaccharides on systemic lupus erythematosus-like syndrome induced by Campylobacter jejuni in BALB/c mice. *Inflammation* 2011; **34**: 402-411 [PMID: 20814813 DOI: 10.1007/s10753-010-9247-7]

116. **Wang Z**, Xie JY, Xu H, Cheng XQ, Yue XL, Li H, Zhang, YY, Lu Y, Chen DF. [Effect of Matteuccia struthiopteris polysaccharides on systemic lupus erythematosus-like syndrome induced by Campylobacter jejuni in BALB/c mice]. *Yao Xue Xue Bao* 2010; **45**: 711-717 [PMID: 20939178]

117. **Verdu EF**, Mauro M, Bourgeois J, Armstrong D. Clinical onset of celiac disease after an episode of Campylobacter jejuni enteritis. *Can J Gastroenterol* 2007; **21**: 453-455 [PMID: 17637949]

118. **Gupta V**, Kohli A. Celiac disease associated with recurrent Guillain-Barré syndrome. *Indian Pediatr* 2010; **47**: 797-798 [PMID: 21048269 DOI: 10.1007/s13312-010-0105-3]

119. **Alaedini A**, Green PH, Sander HW, Hays AP, Gamboa ET, Fasano A, Sonnenberg M, Lewis LD, Latov N. Ganglioside reactive antibodies in the neuropathy associated with celiac disease. *J Neuroimmunol* 2002; **127**: 145-148 [PMID: 12044986 DOI: 10.1016/S0165-5728(02)00102-9]

120. **Sabayan B**, Foroughinia F, Imanieh MH. Can Campylobacter jejuni play a role in development of celiac disease? A hypothesis. *World J Gastroenterol* 2007; **13**: 4784-4785 [PMID: 17729402]

121. **Turpie DF**, Forbes KJ, Hannah A, Metcalfe MJ, McKenzie H, Small GR. Food-the way to a man's heart: a mini-case series of Campylobacter perimyocarditis. *Scand J Infect Dis* 2009; **41**: 528-531 [PMID: 19396664 DOI: 10.1080/00365540902913486]

122. **De Cock D**, Hiltrop N, Timmermans P, Dymarkowski S, Van Cleemput J. Myocarditis associated with Campylobacter enteritis: report of three cases. *Circ Heart Fail* 2012; **5**: e19-e21 [PMID: 22438523 DOI: 10.1161/CIRCHEARTFAILURE.111.964882]

123. **Kratzer C**, Wolf F, Graninger W, Weissel M. Acute cardiac disease in a young patient with Campylobacter jejuni infection: a case report. *Wien Klin Wochenschr* 2010; **122**: 315-319 [PMID: 20559889 DOI: 10.1007/s00508-010-1381-6]

124. **Heinzl B**, Kostenberger M, Nagel B, Sorantin E, Beitzke A, Gamillscheg A. Campylobacter jejuni infection associated with myopericarditis in adolescents: report of two cases. *Eur J Pediatr* 2010; **169**: 63-65 [PMID: 19390862 DOI: 10.1007/s00431-009-0985-1]

125. **Alzand BS**, Ilhan M, Heesen WF, Meeder JG. Campylobacter jejuni: enterocolitis and myopericarditis. *Int J Cardiol* 2010; **144**: e14-e16 [PMID: 19168238 DOI: 10.1016/j.ijcard.2008.12.101]

126. **Turley AJ**, Crilley JG, Hall JA. Acute myocarditis secondary to Campylobacter jejuni enterocolitis. *Resuscitation* 2008; **79**: 165-167 [PMID: 18617316 DOI: 10.1016/j.resuscitation.2008.04.021]

127. **Mera V**, Lopez T, Serralta J. Take traveller's diarrhoea to heart. *Travel Med Infect Dis* 2007; **5**: 202-203 [PMID: 17448951 DOI: 10.1016/j.tmaid.2006.11.001]

128. **Pena LA**, Fishbein MC. Fatal myocarditis related to Campylobacter jejuni infection: a case report. *Cardiovasc Pathol* 2007; **16**: 119-121 [PMID: 17317547 DOI: 10.1016/j.carpath.2006.09.007]

129. **Hannu T**, Mattila L, Rautelin H, Siitonen A, Leirisalo-Repo M. Three cases of cardiac complications associated with Campylobacter jejuni infection and review of the literature. *Eur J Clin Microbiol Infect Dis* 2005; **24**: 619-622 [PMID: 16167138 DOI: 10.1007/s10096-005-0001-2]

130. **Reda E**, Mansell C. Myocarditis in a patient with Campylobacter infection. *N Z Med J* 2005; **118**: U1634 [PMID: 16138172 DOI: 10.1186/1471-2334-3-16]

131. **Hamdulay SS**, Brull DJ, Spyrou N, Holdright DR. A diarrhoeal illness complicated by heart failure. *Hosp Med* 2004; **65**: 756-757 [PMID: 15624455]

132. **Cunningham C**, Lee CH. Myocarditis related to Campylobacter jejuni infection: a case report. *BMC Infect Dis* 2003; **3**: 16 [PMID: 12869210 DOI: 10.1161/​CIRCHEARTFAILURE.111.964882]

133. **Wanby P**, Olsen B. Myocarditis in a patient with Salmonella and Campylobacter enteritis. *Scand J Infect Dis* 2001; **33**: 860-862 [PMID: 11760172 DOI: 10.1080/003655401753186213]

134. **Cox ID**, Fluck DS, Joy MD. Campylobacter myocarditis; loose bowels and a baggy heart. *Eur J Heart Fail* 2001; **3**: 105-107 [PMID: 11163743 DOI: 10.1016/S1388-9842(00)00093-3]

135. **Williams A**. First the chicken, then the egg; the heartburn came later. *Med Health R I* 1997; **80**: 163-165 [PMID: 9150682]

136. **Florkowski CM**, Ikram RB, Crozier IM, Ikram H, Berry ME. Campylobacter jejuni myocarditis. *Clin Cardiol* 1984; **7**: 558-559 [PMID: 6488601 DOI: 10.1002/clc.4960071008]

137. **Becker S**, Ejlertsen T, Kristensen B, Norgaard M, Nielsen H. Is the incidence of perimyocarditis increased following Campylobacter jejuni infection? *Eur J Clin Microbiol Infect Dis* 2007; **26**: 927-929 [PMID: 17885773 DOI: 10.1007/s10096-007-0393-2]

138. **Kaul S**, Fishbein MC, Siegel RJ. Cardiac manifestations of acquired immune deficiency syndrome: a 1991 update. *Am Heart J* 1991; **122**: 535-544 [PMID: 1858638 DOI: 10.1016/0002-8703(91)91013-D]

139. **Fica A**, Seelmann D, Porte L, Eugenin D, Gallardo R. A case of myopericarditis associated to Campylobacter jejuni infection in the southern hemisphere. *Braz J Infect Dis* 2012; **16**: 294-296 [PMID: 22729200 DOI: 10.1590/S1413-86702012000300014]

140. **Braun KP**, Theissig F, Ernst H, May M, Krulls-Munch J. [Campylobacter-jejuni-associated hepatitis and myocardial injury]. *Med Klin (Munich)* 2008; **103**: 346-348 [PMID: 18484221 DOI: 10.1007/s00063-008-1042-y]

141. **Gozzard P**, Orr D, Sanderson F, Sandberg M, Kennedy A. Acute transverse myelitis as a rare manifestation of Campylobacterdiarrhoea with concomitant disruption of the blood brain barrier. *J Clin Neurosci* 2012; **19**: 316-318 [PMID: 22133816 DOI: 10.1016/j.jocn.2011.07.005]

142. **Baar I**, Jacobs BC, Govers N, Jorens PG, Parizel PM, Cras P. Campylobacter jejuni-induced acute transverse myelitis. *Spinal Cord* 2007; **45**: 690-694 [PMID: 17297497 DOI: 10.1038/sj.sc.3102012]

143. **Nasr SH**, Radhakrishnan J, D'Agati VD. Bacterial infection-related glomerulonephritis in adults. *Kidney Int* 2013; **83**: 792-803 [PMID: 23302723 DOI: 10.1038/ki.2012.407]

144. Glomerular diseases: Mechanisms of atypical postinfectious glomerulonephritis. *Nat Rev Nephrol* 2013 [PMID: 23296301 DOI: 10.1038/nrneph.2012.275]

145. **Op den Winkel M**, Gulberg V, Weiss M, Ebeling F, Gerbes AL, Samtleben W. Acute postinfectious glomerulonephritis associated with Campylobacter jejuni enteritis-a case report and review of the literature on C. jejuni's potential to trigger immunologically mediated renal disease. *Clin Nephrol* 2010; **74**: 474-479 [PMID: 21084052]

146. **Lind KM**, Gaub J, Pedersen RS. Henoch-Schonlein purpura associated with Campylobacter jejuni enteritis. Case report. *Scand J Urol Nephrol* 1994; **28**: 179-181 [PMID: 7939469 DOI: 10.3109/00365599409180496]

147. **Carter JE**, Cimolai N. IgA nephropathy associated with Campylobacter jejuni enteritis. *Nephron* 1991; **58**: 101-102 [PMID: 1857464 DOI: 10.1159/000186386]

148. **Andrews PI**, Kainer G, Yong LC, Tobias VH, Rosenberg AR. Glomerulonephritis, pulmonary hemorrhage and anemia associated with Campylobacter jejuni infection. *Aust N Z J Med* 1989; **19**: 721-723 [PMID: 2631667 DOI: 10.1111/j.1445-5994.1989.tb00346.x]

149. **Nagashima J**, Hada T, Itoh Y, Kobayashi S, Ueyama H, Yamakado E, Yamakado M, Terano A. [A case of Campylobactor jejuni enteritis complicated by acute onset IgA nephropathy]. *Nihon Naika Gakkai Zasshi* 1988; **77**: 1454-1455 [PMID: 3246563]

150. **Menck H**. [Campylobacter jejuni enteritis complicated by glomerulonephritis]. *Ugeskr Laeger* 1981; **143**: 1020-1021 [PMID: 7233602]

151. **Gadola SD**, Gross WL. Vasculitis in 2011: the renaissance of granulomatous inflammation in AAV. *Nat Rev Rheumatol* 2012; **8**: 74-76 [PMID: 22231230 DOI: 10.1038/nrrheum.2011.218]

152. **Torphy DE**, Bond WW. Campylobacter fetus infections in children. *Pediatrics* 1979; **64**: 898-903 [PMID: 390487]

153. **Rajabally YA**, Sarasamma P, Abbott RJ. Chronic inflammatory demyelinating polyneuropathy after Campylobacter jejuni infection mimicking vasculitic mononeuritis multiplex in a diabetic. *J Peripher Nerv Syst* 2004; **9**: 98-103 [PMID: 15104697 DOI: 10.1111/j.1085-9489.2004.009208.x]

154. **Giménez-Esparza Vich JA**, Argüelles BF, Martin IH, Gutierrez Fernández MJ, Porras Vivas JJ. Recurrence of Henoch-Schonlein purpura in association with colitis. *J Clin Gastroenterol* 2002; **34**: 492-493 [PMID: 11907375 DOI: 10.3748/wjg.v18.i16]

155. **Ben-Smith A**, Gaston JS, Barber PC, Winer JB. Isolation and characterisation of T lymphocytes from sural nerve biopsies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. *J Neurol Neurosurg Psychiatry* 1996; **61**: 362-368 [PMID: 8890774 DOI: 10.1136/jnnp.61.4.362]

156. **Schønheyder HC**, Søgaard P, Frederiksen W. A survey of Campylobacter bacteremia in three Danish counties, 1989 to 1994. *Scand J Infect Dis* 1995; **27**: 145-148 [PMID: 7660078 DOI: 10.3109/00365549509018995]

157. **Santamaría S**, Sáez-Royuela F, Marne C, López Morante A. [Campylobacter jejuni bacteremia and leukocytoclastic vasculitis in a cirrhotic patient]. *Enferm Infecc* *Microbiol Clin* 1993; **11**: 229-230 [PMID: 8512981]

158. **Nagaratnam N**, Goh TK, Ghoughassian D. Campylobacter jejuni-induced vasculitis. *Br J Clin Pract* 1990; **44**: 636-637 [PMID: 2151678]

159. **Cantini F**, Niccoli L, Nannini C, Kaloudi O, Bertoni M, Cassara E. Psoriatic arthritis: a systematic review. *Int J Rheum Dis* 2010; **13**: 300-317 [PMID: 21199465 DOI: 10.1111/j.1756-185X.2010.01540.x]

160. **Lapadula G**, Iannone F, Covelli M, Numo R, Pipitone V. Anti-enterobacteria antibodies in psoriatic arthritis. *Clin Exp Rheumatol* 1992; **10**: 461-466 [PMID: 1458698]

161. **Polk DB**, Peek RM, Jr. Helicobacter pylori: gastric cancer and beyond. *Nat Rev Cancer* 2010; **10**: 403-414 [PMID: 20495574 DOI: 10.1038/nrc2857]

162. **Frisan T**, Cortes-Bratti X, Chaves-Olarte E, Stenerlow B, Thelestam M. The Haemophilus ducreyi cytolethal distending toxin induces DNA double-strand breaks and promotes ATM-dependent activation of RhoA. *Cell Microbiol* 2003; **5**: 695-707 [PMID: 12969375 DOI: 10.1046/j.1462-5822.2003.00311.x]

163. **Guidoboni M**, Ferreri AJ, Ponzoni M, Doglioni C, Dolcetti R. Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives. *Clin Lymphoma Myeloma* 2006; **6**: 289-300 [PMID: 16507206 DOI: 10.3816/CLM.2006.n.003]

164. **Ferreri AJ**, Zucca E. Marginal-zone lymphoma. *Crit Rev Oncol Hematol* 2007; **63**: 245-256 [PMID: 17583528]

165. **Du MQ**. MALT lymphoma: recent advances in aetiology and molecular genetics. *J Clin Exp Hematop* 2007; **47**: 31-42 [PMID: 18040143]

166. **Brauner A**, Brandt L, Frisan T, Thelestam M, Ekbom A. Is there a risk of cancer development after Campylobacter infection? *Scand J Gastroenterol* 2010; **45**: 893-897 [PMID: 20334473 DOI: 10.3109/00365521003734133]

**P-Reviewers:** Bourke B, McMahon J **S-Editor:** Cui XM

**L-Editor: E-Editor:**